HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting

Hing C. Wong, Founder and Chief Executive Officer of HCW Biologics

“The SITC annual meeting provides us with the right venue to make this major update on our T-Cell Engager as a second-generation immunotherapy for cancer, giving us an opportunity to highlight the uniqueness and advantages of HCW11-018b. With our non-Fc based T-Cell Engager program derived from the TRBC platform, we have created a second-generation T-Cell Engager, HCW11-018b. HCW11-018b has demonstrated that the addition of TGFβ-trap and IL-15 components onto a BiTE domain can overcome the deficiencies of BiTE alone for solid tumor therapy.”

Hing C. Wong, Founder and Chief Executive Officer of HCW Biologics

“The feature of our lead T-Cell Engager candidate we recently discovered that it can promote tertiary lymphoid structure formation is unique and exciting. This distinctive feature of HCW11-018b and other TCEs that we built with our TRBC platform is highly differentiated from other BiTEs for solid tumor therapy.”